)
John Tomtishen
Global Head of Cell Therapy Field Application Scientists and Strategic Alliances
Catalent
Strategic Alliances at Catalent, where he is working to build out partnerships to drive Catalent’s cell therapy business and support drug sponsors across the cell therapy development lifecycle. Prior to joining Catalent, John oversaw the global buildout of the IDMO business at Cellares and played a critical role in driving strategic collaborations and partnerships with cell therapy developers from pre-clinical development to post-commercial licensure. Earlier in his career, John played pivotal roles in the filing and approval of the first CAR-T cell therapy, Kymriah™, while at Novartis, as well as the clinical development and commercial filing of Carvykti™ at Legend Biotech.
Sessions
-
23-Jun-2026Insider Interview: Catalent
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}